Objective: To evaluate predictors and long-term prognosis of atrial fibrillation (AF) following cardiac implantable electronic device (CIED) implantation in patients without history of AF.
Introduction
Atrial fibrillation (AF) is the most common cardiac rhythm disorder encountered in clinical practice. It is associated with an increased risk of stroke, hospitalization, and mortality, all of which have a significant impact on health care economic costs. [1] AF is often asymptomatic and is frequently underdiagnosed. [2] In particular, paroxysmal episodes may be missed during clinical evaluation, electrocardiography, and periodic ambulatory telemetry monitoring. Continuous rhythm monitoring with a cardiac implantable electronic device (CIED) is used to diagnose brief episodes of arrhythmia and detection of AF with CIED is common in the absence of clinical evidence of AF. [3, 4] With respect to individuals who have never experienced AF, the CIED approach detects newly developed AF more frequently than do conventional diagnostic methods, which is important given the association of AF with a significantly increased risk of future cardiovascular events. [4, 5] To date, several clinical conditions have been recognized as risk factors for AF. [6] However, the predictors of AF following CIED implantation in patients without a history of AF remain unclear. Therefore, we investigated the measureable risk factors at the time of device implant that predict development of future AF and evaluated long-term clinical outcomes of newly-developed AF in patients with a CIED.
Methods

Study patients
Between May 1994 and April 2014, 1825 consecutive patients were enrolled in the Samsung Medical Center-CIED registry. CIEDs consisted of permanent pacemakers (PPMs), implantable cardioverter-defibrillators (ICD), and cardiac resynchronization therapy (CRT) with or without defibrillation capability that were available in the domestic market during the study period. Each device was implanted according to the classes I-II recommendations of the current ACCF/AHA/HRS guidelines. [7] The inclusion criteria for the present study were as follows: consecutive patients 18 years of age or older, patients who received 1 of the CIEDs described above, which functioned properly throughout the study, and patients who had at least 1 follow-up visit and device interrogation after the implantation procedure. Patients with reimplantation of devices and patients with a previous history of documented AF/flutter were excluded. A total of 880 patients were included in the final analysis. The patient inclusion process for this study is shown in Fig. 1 . For the purpose of analysis, we classified the study population into a nondetected AF (NDAF) group and a CIED-detected AF (CDAF) group according to development of AF over a follow-up period of 7 years.
Data collection and detection of AF
All patients underwent a complete baseline history taking and physical examination, 12-lead electrocardiogram (ECG), laboratory exam, and transthoracic echocardiogram prior to CIED implantation. Clinical, laboratory, and patient outcome data were collected by a trained study coordinator. History of AF was defined as documented AF/flutter on surface ECG or ECG-Holter monitoring of collected data. All of the CIEDs used in this study had the capacity to record episodes of atrial tachyarrhythmia. Patients were followed at 3-to 6-month intervals. PPM devices were interrogated at 6-month intervals, whereas ICD or CRT devices were interrogated at 3-month intervals, and diagnostic information on the devices and clinical information was collected at that time. Device interrogations were adjudicated by 2 electrophysiologists blinded to the patients' clinical events. Intracardiac arrhythmic events were reviewed in each patient during follow-up visits. AF development was defined as any paroxysmal atrial tachyarrhythmia (atrial rate ≥180 beat/min as detected by the device) lasting at least 5 minutes in patients with a dual-chamber device or CRT device. [8] In patients with a singlechamber devices, AF development was defined based on CIED interrogation with device-based diagnostics. [9] Echocardiographic profiles were measured at the echocardiographic core laboratory (Heart Vascular and Stroke Institute, Samsung Medical Center, Seoul, Korea) according to the established protocol of the American Society of Echocardiography. [10] Mitral valve disease was defined as moderate to severe mitral stenosis or 
Clinical outcomes and definitions
The primary outcome was a composite measure of mortality and unplanned cardiovascular readmission during follow-up after device implantation. Secondary outcomes consisted of mortality, heart failure (HF) readmission, stroke readmission, other cardiovascular readmissions, and unplanned cardiovascular readmissions during follow-up. The unplanned cardiovascular readmissions comprised HF readmission, stroke readmission, and other cardiovascular readmissions. HF readmissions were defined as readmissions with a primary diagnosis of HF on the basis of the major and minor clinical criteria described by the Framingham Heart Study. [11] Stroke readmissions were defined as readmissions with a primary diagnosis of cerebral infraction with rapid-onset focal neurologic symptoms lasting at least 24 hours. [5] Other cardiovascular readmissions comprised diagnoses of cardiovascular origin that did not meet the criteria for HF or stroke readmission. The decision for other cardiovascular readmission was left to the physicians' discretion. With respect to patients with multiple readmissions in the registry, we selected the first instance as the index admission. We classified CDAF as persistent AF or paroxysmal AF. Persistent AF was documented AF that continued for at least one week, and other cases were considered to paroxysmal AF.
Statistical analysis
Continuous variables were compared using Student's t-test or the Wilcoxon rank-sum test when applicable and are presented as the mean ± standard deviation or median with interquartile range. Categorical data were analyzed using the Chi-square test. The effects of putative risk factors on future AF were analyzed using a Cox proportional hazard model. Crude hazard ratios (HR) were computed by stepwise addition of risk factors into the model. To assess which variables at the time of implantation were independent risk factors for future AF, we built a multivariate Cox proportional hazard model by adding variables that were significant (P < 0.10) into the univariate models. Adjusted hazard rates were compared by a Cox proportional hazard model based on age at the time of the procedure, male sex, prior HF, prior sinus node dysfunction, prior symptomatic atrioventricular (AV) block, an LA volume index ≥38.5 mL/m 2 , use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, and use of antiplatelet therapy, starting with the variable that showed the strongest association first. The Cox proportional model assumption was validated by a Schoenfeld residual plot. With respect to clinical outcomes according to development of AF, cumulative event rates were estimated by the Kaplan-Meier method and were compared using log-rank tests. Receiver-operating characteristic curve analysis was performed to estimate LA volume index for new development of AF based on an estimated area under the curve. Statistical analyses were performed with SAS 9.2 (SAS Institute Inc., Cary, NC, USA). All tests were 2 tailed, and P values < 0.05 were considered statistically significant.
Results
Baseline characteristics
Among the 1825 registered patients, 296 patients with reimplanted CIEDs and 649 patients with previous documented AF/flutter at the time of the CIED implantation procedure were excluded. The remaining 880 patients were classified into 2 groups, namely, the NDAF group (n=758) and the CDAF group (n=112), according to development of AF over a follow-up period of 7 years. The overall median follow-up period was 55.2 (IQR 20.0-90.2) months, 75.0 (IQR 37.1-120.0) months in the CDAF group and 51.1 (IQR 18.1-97.6) months in the NDAF group. The baseline characteristics of the 2 groups at the time of CIED implantation are shown in Table 1 . The frequency of CIED Table 1 Baseline characteristics in patients with cardiac implantable electronic device without prior documented AF.
Patients with cardiac implantable electronic devices (n = 880)
Age at procedure, y 64. with atrial lead was lower in the CDAF group than in the NDAF group (41.8 vs 63.1%, P < 0.001). According to medical history data, the frequency of prior sinus node dysfunction was higher in the CDAF group compared to the NDAF group (45.1 vs 23.6%, P < 0.001), whereas the frequency of prior symptomatic AV block was lower in the CDAF group (41.0 vs 56.3%, P=0.002).
Regarding the echocardiographic profile, the frequency of LA volume index ≥38.5 mL/m 2 was higher in the CDAF group than in the NDAF group (67.7 vs 84.4%, P < 0.001). There were no other significant differences in baseline characteristics between the 2 groups. The baseline characteristics of the CDAF and NDAF groups in the PPM subgroup and ICD or CRT subgroups are shown in Tables S1 and S2 in the Supplementary Appendix, http://links.lww.com/MD/B118.
Incidence and predictors of AF
Overall, 122 of the 880 (13.8%) patients included in this study experienced newly developed AF during the follow-up period. The median duration from the implantation procedure date to development of AF was 17.2 (IQR 1.8-50.3) months. The mean age at development of AF was 66.3 ± 14.3 years. In the PPM subgroup, 92 of the 697 (13.2%) patients experienced newly developed AF. The median duration to development of AF was 17.2 (IQR 1.9-52.4) months and the mean age at development of was 69.4 ± 13.3 years. In the ICD and CRT subgroups, 30 of the 183 (16.4%) patients experienced newly developed AF. The median duration to development of AF was 16.2 (IQR 1.6-42.3) months and the mean age at development of AF was 57.1 ± 13.2 years. The Kaplan-Meier curves demonstrated that patients in the ICD or CRT subgroup experienced higher rates of new AF development than did patients in the PPM subgroup during the follow-up period (Log rank P = 0.035; Fig. 2 ).
Significant univariate predictors of AF development were prior HF, prior sinus node dysfunction, prior symptomatic AV block, LA volume index ≥38.5 mL/m 2 , and use of antiplatelet therapy. According to a multivariate Cox regression model, the independent predictors for AF development were prior HF (hazard ratio [HR] 2.40; 95% confidence interval [CI] 1.50-3.85; P < 0.001), prior sinus node dysfunction (HR 2.33; 95% CI 1.62-3.55; P < 0.001), and LA volume index ≥38.5 mL/m 2 (HR 2.01; 95% CI 1.23-3.30; P = 0.005) ( Table 2 ; upper). An additional modified univariate model and multivariate Cox regression model, which excluded CRT devices, showed identical independent predictors for AF development (Table 2 ; lower). In the PPM subgroup, the independent predictors for AF development in the multivariate analysis were age at the time of the procedure (HR 1.02; 95% CI 1.00-1.04; P = 0.04), prior HF (HR 2.05; 95% CI 1.05-4.01; Adjusted covariates include age at procedure, male gender, prior heart failure, prior sick sinus syndrome, prior symptomatic atrioventricular block, left atrial volume index of 38.5 mL/m 2 or more, ACE inhibitor or ARB therapy, and antiplatelet therapy.
† Adjusted covariates include age at procedure, male gender, prior heart failure, prior sick sinus syndrome, prior symptomatic atrioventricular block, left atrial volume index of 38.5 mL/m 2 or more, and antiplatelet therapy.
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Medicine P = 0.03), prior sinus node dysfunction (HR 15.4; 95% CI 7.94-29.86; P < 0.001), and prior symptomatic AV block (HR 5.89; 95% CI 3.08-11.25; P < 0.001) ( Table 3 ). In the ICD and CRT subgroups, the only independent predictor for AF development in the multivariate analysis was LA volume index ≥38.5 mL/ m 2 (HR 4.03; 95% CI 1.54-10.56; P = 0.004) ( Table 4 ).
Long-term clinical outcomes according to AF development
During the follow-up period, a primary endpoint event, defined as a composite outcome of mortality and unplanned cardiovascular readmission, occurred in 40 patients (32.8%) in the CDAF group and 122 patients (16.1%) in the NDAF group (Log rank P < 0.001) (Fig. 3A) . Unplanned cardiovascular readmission occurred in 39 patients (32.0%) in the CDAF group and 102 patients (13.5%) in the NDAF group (Log rank P < 0.001) (Fig. 3B) . HF readmission occurred in 18 patients (14.8%) in the CDAF group and 22 patients (2.9%) in the NDAF group (Log rank P < 0.001) (Fig. 3C ). Stroke readmission occurred in 7 patients (5.7%) in the CDAF group and 6 patients (0.8%) in the NDAF group (Log rank P < 0.001) (Fig. 3D) . Table 5 represents the clinical outcomes of the study population and a comparison of the unadjusted and adjusted hazard ratios between the CDAF and NDAF groups in patients with any type of CIED and in each device subgroup. Overall, the CDAF group, compared to the NDAF group, had a higher risk of unplanned cardiovascular readmission (adjusted HR 2.20; 95% CI 1.50-3.23; P < 0.001), HF readmission (adjusted HR 3.79; 95% CI 1.99-7.22; P < 0.001), stoke readmission (adjusted HR 5.33; 95% CI 1.58-17.97; P = 0.007), and composite outcome of mortality and unplanned cardiovascular readmission (adjusted HR 1.93; 95% CI 1.34-2.78; P < 0.001). There was no statistical difference with respect to the incidence of mortality and other cardiovascular readmissions between the CDAF and NDAF groups. In the PPM subgroup, the CDAF group had a higher risk of HF readmission (adjusted HR 3.38; 95% CI 1.47-7.74; P = 0.004) and stroke readmission (adjusted HR 5.17; 95% CI 1.44-18.50; P = 0.01). In the ICD or CRT subgroups, the CDAF group had a higher risk of HF readmission (adjusted HR 2.67; 95% CI 1.41-5.05; P = 0.002) and composite outcome of mortality and unplanned cardiovascular readmission (adjusted HR 2.56; 95% CI 1.39-4.71; P = 0.002).
Clinical outcomes according to type of AF
In patients with newly developed AF, 46 patients (37.7%) had persistent AF and 76 patients (62.3%) had paroxysmal AF. Table 6 shows the clinical outcomes according to type of AF. During the follow-up period, there were no significant differences in the clinical outcomes between patients with persistent AF and those with paroxysmal AF. 
Discussion
The results of this study can be summarized as follows: In patients without previously documented AF with CIEDs, the rate of newly developed AF was 13.8% over a 7-year follow-up period; prior history of HF, sinus node dysfunction, and large left atrium (LA) volume index were significant predictors for new development of AF in patients with CIED, and the predictors of AF development were different between the PPM subgroup and the ICD and CRT subgroups; and newly developed AF in patients with CIED was significantly associated with an increased risk of HF and stroke readmission according to long-term follow-up data. Despite a lack of any associated clinical symptoms, AF is frequently noticed during continuous rhythm monitoring in patients with implanted CIED, [4, 5, 8, 12] and patients with CIEDs constitute a growing and unique population. Thus, the information in this study regarding newly developed AF in patients with CIED may present a useful opportunity to gain a better understanding of the natural time course of AF, of which little is presently known.
Several studies of patients with pacemakers have reported that the incidence of AF and the predictive value of AF vary considerably over a given range of atrial rates and/or event durations. [12] A recent randomized trial, the Asymptomatic AF and Stroke Evaluation in Pacemaker Patients and the AF Reduction Atrial Pacing Trial (ASSERT), reported that subclinical AF (more than 190 beat/min lasting more than 6 minutes) can be detected in 35% of patients with a newly implanted pacemaker or ICD over a mean 2.5 years of follow-up. [5] In our study, AF development was defined as paroxysmal atrial tachyarrhythmia (atrial rate ≥180 beat/min detected on the device) lasting at least 5 minutes, the rate of which was 13.8% over a 7-year follow-up. The rate detected in the present study was lower than in other study, [12] which may have been because of the age difference and baseline characteristics of the patient population. Patients enrolled in the present study were much younger than patients in the ASSERT trial and consisted entirely of East Asians (Koreans). Aging is a well-known risk factor for the development of AF, [13, 14] and ethnic differences in AF development have been reported in observational studies. Indeed, a large-cohort study showed that Asians have a significantly lower incidence of AF than Whites do. [15] A systematic review of worldwide population-based studies also revealed that the age-adjusted AF incidence rate is lowest among individuals from the Asia Pacific region. [16] The risk factors for new development of AF in patients with CIEDs that we found were consistent with those reported by previous studies. Prior HF is an established risk factor for the development of AF in cross-sectional and cohort population studies using conventional detection methods. [6] Likewise, the ASSERT study and Canadian Trial of Physiologic Pacing both demonstrated that sinus node dysfunction is associated with an increased risk of AF. [5, 17] The clinical association of these 2 diseases has long been recognized, suggesting that both diseases are associated with atrial structural remodeling. [18] Even before the development of atrial arrhythmia, patients with other conditions associated with atrial remodeling and atrial stretch may demonstrate significant sinus node dysfunction. [19] In several previous cohort studies, enlarged LA was identified as a significant risk factor for AF, [20] and another cross-sectional study found a higher prevalence of AF among individuals with a dilated LA compared with those with a normal-sized LA. [21] Our data also demonstrated that a large LA volume index is an independent predictor for newly detected AF in patients with CIEDs. In the subgroup analysis of the present study, the risk factors for new development of AF were different between the PPM subgroup and the ICD and CRT subgroups, which may have been due to different baseline characteristics of the patient population between the 2 groups (See Table S3 in the Supplementary Appendix, http://links.lww.com/MD/B118).
With respect to long-term clinical outcomes, our data demonstrated an increased risk of unplanned cardiovascular readmission and composite mortality and unplanned cardiovascular readmission in the CDAF group, which were driven by higher rates of HF readmission and stroke readmission; however, there was no difference in the risks of mortality and other cardiovascular readmissions compared to the NDAF group. Previous studies have reported an increased risk of stroke events associated with devicedetected atrial tachyarrhythmia, [4, 5] and a similar tendency was noted in our results. By extending the follow-up duration, we found that the risk of unplanned cardiovascular readmissions was higher in the CDAF group compared to the NDAF group. In particular, a higher risk of HF readmission was associated with a higher risk of unplanned cardiovascular readmission over a follow-up period of 7 years. In the present study, clinical outcomes according to type of AF were not significantly different. This result is not consistent with post hoc analysis of a recent randomized trial, which demonstrated that patients with persistent AF have a higher risk of thromboembolic events and a worse survival rate compared with those with paroxysmal AF. [22] Our population was too small to evaluate clinical outcomes according to type of AF, even though AF detection was based on CIEDs.
These data suggest that more CDAF data can be collected from CIEDs for the purpose of risk stratification. Further studies will be required to determine if appropriate CDAF management can significantly affect morbidity and mortality. 
Limitations
There were some limitations to the present study. First, the study design was nonrandomized, retrospective, and observational, which may have significantly affected the results owing to confounding factors. Although we performed multivariate analysis to adjust for these potential confounding factors, we were not able to correct for unmeasured variables. In particular, because of limitations in the patient database, we did not have information on several important factors, such as thyroid disease, cancer, and chronic pulmonary disease. A relatively small number of variables were included in the multivariate Cox proportional hazard model, which may have reduced the detection power and possibly influenced the validity of interactions. Second, this study was performed in a Korean population, the particular features of which most likely influenced the rate of AF and patient outcomes, as different races and populations have different levels of absolute risk, so the results are not generalizable. [16, 23, 24] Third, a measure of the ventricular pacing burden was not available in our study. In previous studies on pacemakers, ventricular pacing was shown to be correlated with increased rates of AF and HF readmission. [25, 26] Because of the retrospective nature of our registry, we could not fully evaluate clinical outcomes according to the cumulative percentage of ventricular pacing burden.
Conclusions
Continuous rhythm monitoring using CIEDs revealed the frequent occurrence of AF after device implantation in patients without a previous history of AF. A prior history of HF, sinus node dysfunction, and large LA volume index were identified as significant predictors of new development of AF in patients with CIEDs. In addition, newly developed AF was significantly associated with an increased risk of HF and stroke readmission. These data suggest that more CDAF data from patients with CIEDs should be collected and used for risk stratification.
